2197.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 11:08):

Stats
Šios dienos apimtis	4.37M
Vidutinė apimtis	1.28M
Rinkos kapitalizacija	454.55M
EPS	HKD0 ( 2024-03-25 )
Kita pelno data	( HKD0 ) 2024-05-29
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-3.08
ATR14	HKD0.00300 (0.80%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: -0.33 (neutral)

Signal:(49.575) Neutral

Clover Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Clover Koreliacija - Valiuta/Žaliavos

-0.50
( weak negative )

-0.23
( neutral )

0.00
( neutral )

-0.79
( moderate negative )

0.84
( strong )

0.81
( strong )

Clover Finansinės ataskaitos

Annual	2023
Pajamos:	HKD39.26M
Bruto pelnas:	HKD-1.67B (-4 262.30 %)
EPS:	HKD-0.110

FY	2023
Pajamos:	HKD39.26M
Bruto pelnas:	HKD-1.67B (-4 262.30 %)
EPS:	HKD-0.110

FY	2022
Pajamos:	HKD0
Bruto pelnas:	HKD-475.64M (0.00 %)
EPS:	HKD-2.22

FY	2021
Pajamos:	HKD0.00
Bruto pelnas:	HKD0.00 (0.00 %)
EPS:	HKD-5.19

Financial Reports:

No articles found.

Clover

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.